Malaria treatment failures after artemisinin-based therapy in three expatriates: Could improved manufacturer information help to decrease the risk of treatment failure?

  • Jackson Y
  • Chappuis F
  • Loutan L
 et al. 
  • 21

    Readers

    Mendeley users who have this article in their library.
  • 14

    Citations

    Citations of this article.

Abstract

BACKGROUND: Artemisinin-containing therapies are highly effective against Plasmodium falciparum malaria. Insufficient numbers of tablets and inadequate package inserts result in sub-optimal dosing and possible treatment failure. This study reports the case of three, non-immune, expatriate workers with P. falciparum acquired in Africa, who failed to respond to artemisinin-based therapy. Sub-therapeutic dosing in accordance with the manufacturers' recommendations was the probable cause.

METHOD: Manufacturers information and drug content included in twenty-five artemisinin-containing specialities were reviewed.

RESULTS: A substantial number of manufacturers do not follow current WHO recommendations regarding treatment duration and doses.

CONCLUSION: This study shows that drug packaging and their inserts should be improved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Yves Jackson

  • François Chappuis

  • Louis Loutan

  • Walter Taylor

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free